Soa Tsung
Internal Medicine · Menlo Park, CANPI 1992810063
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $800 and has fallen 90.5% since, to $76 in 2025.
Across 88 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$333
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$263
- Therapeuticsmd, Inc.$129
- Neurocrine Biosciences, Inc.$127
- Mylan Specialty L.p.$114
- Takeda Pharmaceuticals U.S.A., Inc.$108
- plus $678 from 15 others
What the payments were for
- Food & beverage$1,751100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 15 | $333 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $263 |
| Therapeuticsmd, Inc. | 6 | $129 |
| Neurocrine Biosciences, Inc. | 5 | $127 |
| Mylan Specialty L.p. | 6 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $108 |
| Bausch Health US, LLC | 5 | $104 |
| Pfizer | 6 | $96 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $68 |
| Ardelyx, Inc. | 2 | $57 |
| Merck | 3 | $56 |
| AstraZeneca | 2 | $46 |
| Alfasigma USA, Inc. | 2 | $44 |
| Amgen(2 entities) | 2 | $40 |
| Sanofi Pasteur Inc. | 2 | $40 |
| Novo Nordisk | 1 | $28 |
| IBSA Pharma Inc. | 1 | $23 |
| Vertical Pharmaceuticals, LLC | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Viatris Specialty LLC | 1 | $19 |
| Shionogi Inc | 1 | $15 |
How this compares
$1,751 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BenicarOlmesartan Medoxomil | 15 | $14,001 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $8,959 |
| LinzessLinaclotide | 11 | $7,754 |
| SynthroidLevothyroxine Sodium | 69 | $7,030 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,302 |
| PaxlovidNirmatrelvir/Ritonavir | 17 | $4,288 |
| Atorvastatin Calcium | 69 | $842 |
| Liothyronine Sodium | 30 | $839 |
| Sodium ChlorideSodium Chloride Irrig Solution | 13 | $800 |
| Oxycodone Hcl | 26 | $739 |
| Pregabalin | 15 | $715 |
| ValacyclovirValacyclovir Hcl | 15 | $623 |
| DottiEstradiol | 15 | $592 |
| Amlodipine Besylate | 40 | $501 |
| Clonazepam | 14 | $458 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Synthroid | $333 | $14,78480 claims |
| Daiichi Sankyo Inc.Benicar | $21 | $14,00115 claims |
| PfizerPaxlovid | $96 | $4,28817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Menlo Park
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.